Abstract:Rationale: Genetic editing has shown great potential for the treatment of human hereditary disorders via the elimination of mutations in embryos. However, the efficiency and safety of germline gene editing are not well understood. Objective: We aimed to examine the preclinical efficacy/safety of embryonic base editing in a mouse model of hypertrophic cardiomyopathy (HCM) using a novel adenine base editor (ABE) platform. Methods and Results: Here, we described the use of an ABEmax-NG to directly correct the pathogenic R404Q/+ mutation (Myh6 c.1211C>T) in embryos for a mouse model of HCM, increasing the number of wild-type embryos for in vitro fertilization. Delivery of the ABEmax-NG mRNA to embryos from R404Q/+ HCM mice resulted in 62.5-70.8% correction of the Myh6 c.1211C>T, reducing the level of mutant RNA and eliminating HCM in the post-natal mice as well as their offspring. In addition, the same sgRNA was also used to target an intronic locus (TGG PAM) with an overall editing rate of 86.7%, thus confirming that ABEmax-NG can efficiently edit target loci with different PAMs (NG) and genomic distribution in vivo. Compared with CRISPR/ssODN-mediated correction, ABEmax-NG displayed a much higher correction rate without introducing indels. DNA and RNA off-target analysis did not detect off-target editing in treated embryos and founder mice. In utero injection of adeno-associated virus 9 (AAV9) encoding the ABEmax-NG also resulted in around 25.3% correction of the pathogenic mutation and reduced of mutant RNA, thereby indicating ABEmax-NG has the potential to correct the HCM mutation in vivo. Conclusions: We developed an ABEmax-NG system, which efficiently corrected a pathogenic Myh6 HCM mutation in mouse embryos without off target lesions, thus safely eliminating HCM in derived mice and their progeny.

Prime editor-mediated correction of a pathogenic mutation in purebred dogs

Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases

Comparison of In-Frame Deletion, Homology-Directed Repair, and Prime Editing-Based Correction of Duchenne Muscular Dystrophy Mutations

Precise editing of pathogenic nucleotide repeat expansions in iPSCs using paired prime editor

Dual-AAV split prime editor corrects the mutation and phenotype in mice with inherited retinal degeneration

Correction of Beta-Thalassemia IVS-II-654 Mutation in a Mouse Model Using Prime Editing

Deletion and replacement of long genomic sequences using prime editing

Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG

Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy

A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing

Evolution of Prime Editing Systems: Move Forward to the Treatment of Hereditary Diseases

Treatment of a genetic liver disease in mice through transient prime editor expression

Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing

A robust and inducible precise genome editing via an all-in-one prime editor in human pluripotent stem cells

Toward the correction of muscular dystrophy by gene editing

Correction of a pathogenic gene mutation in human embryos

Search-and-replace genome editing without double-strand breaks or donor DNA

Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing

In vivo prime editing of a metabolic liver disease in mice

Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression

Genome editing using Staphylococcus aureus Cas9 in a canine model of glycogen storage disease Ia